Psilocybin vs Ketamine: Mechanism, Access, and Evidence

TL;DR

Psilocybin and ketamine are the two most-studied psychiatric psychedelics, but they sit in very different places clinically:

• Ketamine is legal, prescribable, and clinically established for treatment-resistant depression. Sessions last 1–2 hours; antidepressant effects often appear within hours.
• Psilocybin remains Schedule I federally. Legal access exists only via clinical trials, the Oregon state psilocybin services program, and Colorado's regulated program. Sessions last 6–8 hours.
• Mechanisms differ: ketamine blocks NMDA glutamate receptors; psilocybin activates serotonin 5-HT2A receptors. Both increase neuroplasticity but via different pathways.
• For an option you can use today, ketamine is the answer. Psilocybin is promising but still mostly research-phase access.

How they work: different receptors, similar downstream effects

Ketamine

Ketamine blocks NMDA glutamate receptors, triggering a cascade that increases AMPA receptor activation, BDNF release, and synaptic remodeling — particularly in the prefrontal cortex and hippocampus. Subjective experience: dissociation, dreamlike inwardness, time distortion. Mood improvement often appears within hours of dosing.

Psilocybin

Psilocybin is metabolized to psilocin in the bloodstream, which activates the serotonin 5-HT2A receptor. This produces classic psychedelic effects — visual imagery, altered self-perception, deep emotional access — and resets activity patterns across large-scale brain networks. Mood improvements typically emerge days after a session and can last weeks to months.

Where they converge

Both trigger neuroplastic changes that outlast the acute experience. The mechanisms differ but the downstream effect — a window during which old depressive thought patterns become more changeable — looks similar. Integration work afterward is what translates either experience into durable behavior change.

Clinical evidence

Ketamine

Decades of evidence, anchored by:

• Berman et al., 2000 — first controlled trial showing rapid antidepressant effects (Biological Psychiatry)
• Zarate et al., 2006 — antidepressant response within 2 hours in TRD (Archives of General Psychiatry)
• Spravato (esketamine) FDA-approved 2019 for TRD

Psilocybin

Strong but earlier-stage evidence:

• Davis et al., 2021 — psilocybin-assisted therapy produced large antidepressant effects in MDD, comparable to or better than standard antidepressants (JAMA Psychiatry)
• Carhart-Harris et al., 2021 — psilocybin showed non-inferiority to escitalopram (an SSRI) in major depression in a 6-week trial (New England Journal of Medicine)
• Goodwin et al., 2022 — single dose of psilocybin in TRD produced rapid, durable improvements at 3 weeks (NEJM)

The psilocybin evidence is strong but the regulatory pathway is incomplete — no FDA-approved psilocybin product exists yet (as of 2026).

Side-by-side comparison

Feature	Ketamine	Psilocybin
Drug class	Dissociative anesthetic	Classic psychedelic
U.S. legal status	Schedule III; legal Rx	Schedule I federally; legal in Oregon + Colorado state programs
FDA approval	Spravato for TRD; off-label racemic	None yet
Primary mechanism	NMDA receptor antagonism	5-HT2A receptor agonism
Session length	1–2 hours	6–8 hours
Acute experience	Dissociation, dreamlike	Visual, emotional, ego-dissolution
Antidepressant onset	Hours	Days
Duration of effect (per session)	1–2 weeks typical	Weeks to months in trials
Access today	Telehealth + at-home prescription	Clinical trials + Oregon/Colorado programs
Typical session cost (out of pocket)	$398/mo at-home oral; $400–800/IV	$1,500–3,500 in Oregon program
Provider type	Physician (MD/DO)	Licensed psilocybin facilitator (Oregon)

Legal access reality check

The legality gap is the single biggest practical difference between these two options today.

Ketamine is available through:

• Physician prescription in all 50 states (off-label or via Spravato)
• Telehealth platforms with in-state physicians (including Isha Health)
• IV clinics in most major cities

Psilocybin is available through:

• Oregon Psilocybin Services — adults 21+ can access regulated sessions at licensed service centers (no diagnosis required, but no medical/insurance integration either)
• Colorado Natural Medicine — similar model, ramping up since 2024
• Clinical trials — listed at ClinicalTrials.gov under terms like "psilocybin depression"
• Not available through standard prescription in any U.S. state

If you live outside Oregon or Colorado and can't enroll in a trial, psilocybin therapy via legal U.S. channels is not currently an option.

Microdosing: caveats

Microdosing both ketamine and psilocybin has become culturally popular, but the evidence picture is different:

• Ketamine microdosing (10–25 mg sublingual) is sometimes used clinically as maintenance dosing between standard-dose sessions. Evidence is limited but the clinical context is reasonable.
• Psilocybin microdosing (~0.1–0.3 g dried mushroom) has been studied in multiple placebo-controlled trials, and the consistent finding is that subjective benefits track placebo expectancy — people who think they took a microdose feel benefits regardless of whether they actually did. The neuroplasticity case at microdose levels is also much weaker than at full doses.

If you're considering microdosing for mental health, the harder question to answer than "ketamine vs psilocybin?" is "is microdosing worth it at all?"

Which one might be a better fit?

Treatment-decision factors — assuming you have legal access to both:

• Need rapid relief (acute suicidality, severe TRD): ketamine. Antidepressant effect in hours vs. days.
• Want a longer, more visually intense experience: psilocybin sessions are 6–8 hours and produce richer perceptual content.
• Don't tolerate dissociation well: psilocybin may be a softer fit; ketamine's dissociative state is harder for some patients.
• Have a TRD diagnosis and want insurance coverage: Spravato (esketamine) is the FDA-approved option.
• Live in Oregon or Colorado and want a non-medical legal psilocybin experience: the state programs are the legitimate path.
• Live anywhere else and want a legal, available option: ketamine.

Safety considerations

Both have favorable safety profiles under supervision but require screening:

Ketamine

• Transient blood pressure elevation, dissociation, nausea during sessions
• Chronic high-frequency recreational use: bladder dysfunction, cognitive effects (see does ketamine cause memory loss)
• Caution with: uncontrolled hypertension, certain psychiatric conditions

Psilocybin

• Physiologically benign at therapeutic doses
• Acute psychological risk: anxiety, panic, overwhelming experience without preparation/support
• Contraindicated: personal or family history of psychotic disorders, bipolar disorder (some protocols)
• Drug interactions: SSRIs may blunt the experience; lithium has been associated with seizure risk

FAQs

Is psilocybin more effective than ketamine?

Neither has been shown to be definitively more effective in head-to-head trials. The Carhart-Harris 2021 NEJM trial showed psilocybin non-inferior to an SSRI; head-to-head psilocybin-vs-ketamine trials don't yet exist. Practically, the answer depends on which one you can legally access.

Can you do ketamine and psilocybin together?

There is no established clinical protocol for co-administration. Some experimental sequential protocols are being studied. Outside research, combining them is not recommended.

Is psilocybin microdosing safer than ketamine therapy?

It depends what you mean by safer. Microdosing involves much smaller doses than full-dose sessions, so acute risk is lower — but the evidence for benefit at microdose levels is weak (largely placebo-tracked). Therapeutic ketamine sessions under physician supervision have a long safety track record and well-documented benefit. "Safer" in the abstract doesn't mean "more useful."

Which is more natural — ketamine or psilocybin?

Psilocybin is naturally produced by certain mushroom species; ketamine is synthetic. "Natural" doesn't track with safety or effectiveness, though — caffeine is natural and nicotine is natural. Mechanism, evidence, and supervision are what matter.

Will psilocybin be FDA-approved soon?

Compass Pathways and Usona Institute both have psilocybin in late-stage clinical trials. An FDA approval for psilocybin-assisted therapy in TRD is plausible in the next few years but not guaranteed. Timeline depends on trial outcomes and FDA review.

---

Related Articles

• DMT vs Ketamine: Mechanisms, Therapy, Legal Status
• Spravato vs Ketamine Infusion
• Ketamine vs SSRIs: Fast Relief Or Long-Term Treatment?

---

Considering ketamine therapy? Ketamine is currently the only psychedelic-adjacent therapy legally available in all 50 states. Isha Health offers physician-led at-home treatment with an 88.8% improvement rate. Check appointment availability.